Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 04, 2013 07:00 ET | Source: Boston Therapeutics

Boston Therapeutics Reports Positive Phase II Results of PAZ320 Are Published in July/August Issue of Endocrine Practice

MANCHESTER, NH--(Marketwired - Sep 4, 2013) - Boston Therapeutics, Inc. (OTCQB: BTHE) ("Boston Therapeutics" or "the Company"), a developer of complex carbohydrates to treat diabetes and...
August 09, 2013 10:58 ET | Source: Boston Therapeutics

Boston Therapeutics Reports Financial Results and Corporate Update for the Second Quarter and Six Months Ended June 30, 2013

MANCHESTER, NH--(Marketwired - Aug 9, 2013) - Boston Therapeutics, Inc. (OTCQB: BTHE) ("Boston Therapeutics" or "the Company"), a drug development company focused on complex carbohydrates to...
August 02, 2013 07:30 ET | Source: Boston Therapeutics

Boston Therapeutics to Exhibit at 2013 American Association of Diabetes Educators Annual Meeting & Exhibition in Philadelphia

MANCHESTER, NH--(Marketwired - Aug 2, 2013) - Boston Therapeutics, Inc. (OTCQB: BTHE) ("Boston Therapeutics" or "the Company"), a pharmaceutical company developing and commercializing complex...
May 15, 2013 16:10 ET | Source: Boston Therapeutics

Boston Therapeutics Reports First Quarter 2013 Results

MANCHESTER, NH--(Marketwired - May 15, 2013) - Boston Therapeutics, Inc. (OTCQB: BTHE) ("Boston Therapeutics" or "the Company"), a pharmaceutical company developing and commercializing complex...
April 11, 2013 07:00 ET | Source: Boston Therapeutics

Boston Therapeutics Requests an IND Meeting With the FDA for PAZ320 to Reduce Postprandial Hyperglycemia in Type 2 Diabetes

MANCHESTER, NH--(Marketwired - Apr 11, 2013) - Boston Therapeutics, Inc. (OTCQB: BTHE) ("Boston Therapeutics" or "the Company"), a pharmaceutical company developing and commercializing complex...
April 08, 2013 07:50 ET | Source: Boston Therapeutics

Boston Therapeutics Featured in Four Publications

MANCHESTER, NH--(Marketwired - Apr 8, 2013) - Boston Therapeutics, Inc. (OTCQB: BTHE) ("Boston Therapeutics" or "the Company"), a pharmaceutical company focused on developing and...
April 04, 2013 16:10 ET | Source: Boston Therapeutics, Inc.

Boston Therapeutics Reports Full Year 2012 Financial Results

MANCHESTER, NH--(Marketwired - Apr 4, 2013) - Boston Therapeutics, Inc. (OTCQB: BTHE) ("Boston Therapeutics" or "the Company"), a developer of complex carbohydrates to treat diabetes and...
March 27, 2013 07:00 ET | Source: Boston Therapeutics, Inc.

Boston Therapeutics Strategically Positioned to Focus Its Pipeline on Commercializing Pharmaceutical Drugs to Treat Diabetes and Inflammatory Disease: To Accelerate Commercialization of PAZ320 & IPOXYN(TM)

MANCHESTER, NH--(Marketwire - Mar 27, 2013) - Boston Therapeutics, Inc. (OTCQB: BTHE) ("Boston Therapeutics" or "the Company"), a pharmaceutical company focused on developing and commercializing...
March 12, 2013 07:00 ET | Source: Boston Therapeutics

Boston Therapeutics Appoints Peter Sheehan, M.D. as Medical Director

MANCHESTER, NH--(Marketwire - Mar 12, 2013) - Boston Therapeutics, Inc. (OTCQB: BTHE) ("Boston Therapeutics" or "the Company"), a developer of complex carbohydrates to treat diabetes and...
February 26, 2013 07:00 ET | Source: Boston Therapeutics

Boston Therapeutics Reports Positive Phase ll Clinical Trial Results of PAZ320 in Patients With Type 2 Diabetes

MANCHESTER, NH--(Marketwire - Feb 26, 2013) - Boston Therapeutics, Inc. (OTCQB: BTHE) ("Boston Therapeutics" or "the Company"), a developer of complex carbohydrates to treat diabetes and...